Tert-Butyl(3S)-3-(2-Oxo-1,2-Dihydro-3H-Imidazo[4,5-B]Pyridin-3-Yl)Pyrrolidine-1-Carboxylate

The molecule tert-butyl (3S)-3-(2-oxo-1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-yl)pyrrolidine-1-carboxylate functions as a chiral 3-aminopyrrolidine surrogate whose imidazopyridinone heterocycle mimics a quinolone or naphthyridone pharmacophore, positioning it as a key intermediate in the assembly of kinase insert domain receptor (KDR) inhibitors, phosphoinositide 3-kinase (PI3K) modulators, and factor Xa antagonists currently under preclinical evaluation. The compound presents a molecular weight of 330.39 g·mol⁻¹, a ClogP of 1.08, and two hydrogen bond acceptors within the oxo-dihydroimidazopyridine ring system, conferring moderate polarity balanced by the lipophilic tert-butyl carbamate (Boc) protecting group. Typical lots isolated from kilogram-scale crystallizations in methyl tert-butyl ether (MTBE)/n-heptane exhibit a specific optical rotation [α]_D²⁰ of –39.8° (c=1.0, MeOH), with batch-to-batch variability held within ±0.5° when crystallisation cooling rates are controlled at 0.3 °C·min⁻¹ in a 50-L glass-lined reactor. Chromatographic purity by achiral HPLC (Inertsil ODS-3, 4.6×150 mm, 5 µm; gradient of 0.1% TFA in water/MeCN) routinely exceeds 99.2 area% at 254 nm, while residual palladium from the preceding Buchwald–Hartwig amination that installs the imidazopyridinone is held below 10 ppm through treatment with trimercaptotriazine-functionalised silica scavenger.

How Does the (3S)-Configuration Influence Pharmacophore Assembly?

Stereochemical integrity at the pyrrolidine 3-position is the defining quality attribute because the imidazopyridinone moiety projects from the ring with a dihedral angle that orients the lactam carbonyl toward the conserved hinge region of ATP-binding pockets in kinase targets. Inverted (3R) configuration would rotate the heterocycle by approximately 120°, altering the vector required for bidentate hydrogen bonding with Met⁷⁶⁹ and Cys⁷⁷³ residues of the epidermal growth factor receptor (EGFR) kinase domain, as inferred from co-crystal structure PDB 4I22. Enantiomeric excess (e.e.) is quantified by chiral HPLC on a Chiralpak IA column (4.6×250 mm, 5 µm) with n-hexane/ethanol/trifluoroacetic acid (80:20:0.1) as mobile phase at 1.0 mL·min⁻¹, where the (S)-enantiomer elutes near 9.2 min and the (R)-antipode at 10.5 min; the limit of quantification for the undesired (R)-isomer is 0.05%. Routine release testing requires e.e. ≥ 99.0% (corresponding to ≤ 0.5% of the (R)-enantiomer). Published data for this specific scaffold is limited, but in-house stability studies demonstrate that the free base generated by Boc deprotection racemizes at 0.2%·h⁻¹ in DMF at ambient temperature, underscoring the critical role of the carbamate in suppressing α-deprotonation. The chiral centre’s configurational stability under acidic Boc-cleavage conditions (TFA/CH₂Cl₂ 1:1, 0 °C, 2 h) is adequate, with e.e. loss not exceeding 0.3%, provided the temperature is maintained below 5 °C.

Physical Form and Pre-Formulation Requirements

Bulk material appears as a white to off-white microcrystalline powder with a melting onset of 147.2 °C (DSC, 10 K·min⁻¹, nitrogen atmosphere, ASTM D3418), preceded by a small endotherm attributed to solvent release at 88–92 °C when residual MTBE exceeds 0.5 wt%. Dynamic vapour sorption analysis at 25 °C indicates a water uptake of 0.35 wt% at 60% RH and 1.8 wt% at 90% RH, classifying the substance as slightly hygroscopic. Solubility at 20 °C exceeds 80 mg·mL⁻¹ in dimethyl sulfoxide and 50 mg·mL⁻¹ in N,N-dimethylformamide, while aqueous solubility is below 0.1 mg·mL⁻¹ in phosphate buffer pH 7.4. Process chemists should pre-dry any lot exposed to relative humidity above 60% for longer than 8 h by holding under vacuum (≤5 mbar) at 40 °C for 16 h before charging into moisture-sensitive amidations; Karl Fischer titration (USP <921> Method Ia) must read ≤ 0.15% water. Prolonged storage above 150 °C triggers exothermic degradation (ΔH = –420 J·g⁻¹ by DSC) and should be avoided in melt-processing evaluations. The compound is incompatible with strong oxidising agents and should be kept separate from peroxides and hypochlorite solutions.

When Coupling Efficiency Drops Below 60% in Imidazopyridine N-Arylations

The most frequently reported process conflict arises during palladium-catalysed N-arylation of the imidazopyridinone NH with electron-deficient aryl bromides using Pd₂(dba)₃/Xantphos systems. While the Boc group remains inert, the imidazopyridinone NH participates in oxidative addition–reductive elimination cycles, but catalyst deactivation by the free pyrrolidine nitrogen—if partial in-situ Boc cleavage occurs—suppresses turnover numbers below 100 and causes yields to plateau below 60%. Maintaining a rigorously anhydrous environment (KF ≤ 50 ppm in dioxane) and an internal temperature window of 80 ± 3 °C is essential: excursions above 83 °C accelerate both Boc thermolysis and epimerisation at the (3S)-centre due to enolate formation mediated by the by-product amine base. In a 20-L jacketed reactor equipped with retreat-curve impeller and temperature ramping limited to 0.5 °C·min⁻¹, the enantiomeric excess can be preserved at 98.7% after 12 h, whereas a batch processed at 88 °C dropped to 94.1% with 4.2% of the (R)-epimer detected. Use of LiHMDS at –20 °C for directed metalation prior to electrophilic trapping avoids this thermal window entirely, enabling coupling yields of 72–81% with e.e. retention > 99.0%, although the cryogenic condition demands a Haake EK90 chiller and limits throughput. An alternative single-electron transfer pathway employing Ni(COD)₂/4,4′-di-tert-butyl-2,2′-bipyridyl in THF at 25 °C has been communicated in a peer-reviewed optimisation study, reporting isolated yields of 68–74% without detectable racemisation, though reproducibility at scale is constrained by the air-sensitivity of the Ni(0) precatalyst.

Epimerisation Tendencies and Electronic Descriptors of Pyrrolidine-Boc Building Blocks

Distinct from the simpler tert-butyl (3S)-3-aminopyrrolidine-1-carboxylate (MW 186.25 g·mol⁻¹, ClogP 0.38), the imidazopyridinone-substituted derivative exhibits a substantially attenuated basicity at the pyrrolidine nitrogen (calculated pKₐ of the conjugate acid ∼ 6.9 versus ∼ 9.5 for the amino analog), which reduces inadvertent protonation during solid-phase peptide synthesis on 2-chlorotrityl chloride resin. The steric footprint of the planar imidazopyridinone further shields the (3S)-methine proton, lowering the rate of base-induced epimerisation by approximately 8-fold relative to the (3S)-amino compound when exposed to DBU in acetonitrile at 40 °C (k = 2.4×10⁻⁴ s⁻¹ vs. 1.9×10⁻³ s⁻¹). Against its (3R)-antipode, the (3S)-isomer’s rotational correlation time in [D₆]DMSO differs by 4% as measured by ¹H NOESY, consistent with a slightly different pyrrolidine ring pucker that affects proton coupling constants (J_4a,4b = 12.8 Hz (S) vs. 13.5 Hz (R)). The unprotected variant, 3-(2-oxo-1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-yl)pyrrolidine, is highly hygroscopic (water uptake > 5 wt% at 50% RH) and is not isolated as a stable solid; its dihydrochloride salt exhibits a solubility advantage in aqueous formulation (≥ 120 mg·mL⁻¹ in water) but demands desiccated storage at –20 °C to prevent hydrolysis of the imidazopyridinone ring. A comparative summary of critical physicochemical determinants is provided in Table 1.

Residual palladium concentrations in final active pharmaceutical ingredients sourced from this intermediate must comply with ICH Q3D Guideline for Elemental Impurities, where the oral permitted daily exposure for palladium is 100 µg·day⁻¹; the in-process specification of 10 ppm provides a comfortable margin assuming a daily dose below 1 g for a compound derived from the intermediate at a fragment-to-drug molecular weight ratio of 1:3. Table 2 collates the routine release testing specifications applied to GMP batches manufactured under ICH Q7 and ISO 9001:2015-certified quality systems. Analytical reference standards of the (R)-enantiomer and the des-Boc impurity are available as secondary pharmacopeial standards traceable to ¹H qNMR quantification with internal calibrant dimethyl sulfone certified to 99.95% purity.

Accelerated stability data generated at 40 °C / 75% RH in triple-laminated polyethylene-aluminium barrier bags over 6 months shows a purity decline from 99.6% to 98.9%, with the main degradant identified as the N-Boc-deprotected pyrrolidine, accumulating at 0.12% per month. At the recommended long-term storage condition of –20 ± 5 °C under argon in amber glass vials containing 3-Å molecular sieve desiccant, no individual impurity exceeds 0.10% over 24 months. Exposure to ambient fluorescent lighting for 48 h produces a detectable photodegradant (0.15%) with a bathochromic shift to 310 nm, prompting a precautionary instruction to shield reaction mixtures from light during extended processing. The compound’s limited mutagenic potential is inferred from a negative Ames test (OECD 471, strains TA98, TA100, TA1535, TA1537 and WP2 uvrA) at concentrations up to 5000 µg·plate⁻¹; this data, together with the absence of structural alerts in Derek Nexus predictions, supports its classification as a non-mutagenic impurity per ICH M7 when present below 1 mg·day⁻¹ in the final drug substance.